MOUNTAINEER:open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress).

John H. Strickler,Kimmie Ng,Andrea Cercek,Christos Fountzilas,Federico Augusto Sanchez,Joleen M Hubbard,Christina Wu,Salvatore Siena,Josep Tabernero,Eric Van Cutsem,Adel Kardosh,Anwaar Saeed,Thierry André,Michael Stecher,Maria Corinna Palanca-Wessels,Tanios Bekaii-Saab

MOUNTAINEER:open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress).

2021

John H. Strickler
Kimmie Ng
Andrea Cercek
Christos Fountzilas
Federico Augusto Sanchez
Joleen M Hubbard
Christina Wu
Salvatore Siena
Josep Tabernero
Eric Van Cutsem
Adel Kardosh
Anwaar Saeed
Thierry André
Michael Stecher
Maria Corinna Palanca-Wessels
Tanios Bekaii-Saab

TPS153Background: The clinical benefit of approved therapies in patients (pts) with metastatic colorectal cancer (mCRC) who progress on first- and second-line chemotherapy (FOLFOX and FOLFIRI) is l...

Keywords:

Oncology
Colorectal cancer
FOLFIRI
Internal medicine
in patient
Phases of clinical research
Trastuzumab
open label
FOLFOX
Chemotherapy
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations